Huadong Medicine's Subsidiary Completes First Cohort Dosing in Phase I Clinical Trial of DR10624 in China

Official WeChat Account of Huadong Medicine reported on October 17 that on October 13, Zhejiang Doer Biologics Co., Ltd., a clinical-stage biopharmaceutical company under Huadong Medicine that develops innovative biotherapeutics for metabolic diseases and cancer, announced the completion of dosing for the first cohort (12 subjects in total) in a Phase I single ascending dose (SAD) clinical trial in China for DR10624, a globally pioneering tri-targeted multispecific innovative drug, intended for weight management in overweight or obese populations.